ClinicalTrials.gg
Sign In
DrugBiological

Factor IX Fc fusion protein clinical trials

Also written Alprolix, BIIB029 and rFIXFc.

studies test it
6
open now
0
in phase 3
4
first study started
2008

How each study uses factor IX Fc fusion protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
12 May 2016 · Alprolix · EMEA/H/C/004142 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

recombinant coagulation factor IX Fc fusion protein
2

Brand

Alprolix
5

Development codes

BIIB029
4

Other names

rFIXFc
4

Studies by the year they started

6 studies that test it; most in 2008 (1)

Studies that test factor IX Fc fusion protein, by start year
YearStudies
20081
20091
20111
20121
20141
20181

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
1
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Hemophilia B
5
Hemophilia A
1

Who runs them

Industry 5 · Other 1

Bioverativ Therapeutics Inc. (4) · Bioverativ, a Sanofi company (1) · Emory University (1)

Often tested with

Tested in the same studies.

Factor IX (1) · Factor VIII-Fc fusion protein (1)

Studies

Open first, then newest update. How each study uses factor IX Fc fusion protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 6

As the comparator · 1 — what is tested is compared with factor IX Fc fusion protein